Compare Organon & Co. Common Stock (OGN) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Paycom Software Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Paycom Software Inc trades at $238.6 (market cap $10.67B). The key difference: Paycom Software Inc is far larger — about 2.9× Organon & Co. Common Stock's market cap, and Paycom Software Inc pays the higher dividend (0.63%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Paycom Software Inc for 84 Days on average.
| OGN | PAYC | |
|---|---|---|
Market Cap | $3.62B | $10.67B |
Volume | 2,892,999 | 411,289 |
Sector | Health | Technology |
52-Week High | $13.81 | $240.52 |
52-Week Low | $5.70 | $113.59 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $11.04B | $11.45B |
Dividend Yield | 0.58% | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PAYC trades at $239.00, up 1.7% today, with a bullish technical trend and strong fundamentals. The company reported Q2 2026 EPS of $2.78, beating estimates by 17%, and raised full-year guidance to 7-8% revenue growth. Valuation metrics show a P/E of 25.04 and robust profitability with a net margin of 22.78%. Recent news highlights institutional buying and positive earnings momentum.
The outlook is positive given earnings beats and raised guidance, but risks include high valuation multiples and competitive pressures. Analysts are mixed with a $211.08 consensus target, below the current price, suggesting cautious optimism. The stock's proximity to its 52-week high warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
